期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
药物综合疗法治疗甲状腺功能亢进合并糖尿病患者临床效果研究 被引量:6
1
作者 张晓红 《系统医学》 2017年第4期55-58,共4页
目的分析药物综合疗法对甲状腺功能亢进合并糖尿病患者的临床治疗效果。方法从该院2014年1月—2015年12月收治的患者中,选取76例患有甲状腺功能亢进合并糖尿病患者为研究对象,采用随机分组的方式,将其分成两组,对照组和观察组各38例,对... 目的分析药物综合疗法对甲状腺功能亢进合并糖尿病患者的临床治疗效果。方法从该院2014年1月—2015年12月收治的患者中,选取76例患有甲状腺功能亢进合并糖尿病患者为研究对象,采用随机分组的方式,将其分成两组,对照组和观察组各38例,对对照组患者采用一般治疗方式,并在此基础上对观察组患者增加药物综合治疗法,并对两组患者的治疗总有效率、血糖水平、甲亢症状的临床改善时间进行观察和比较。结果通过分析比较,对照组达到了55.3%的总有效率,观察组达到了97.4%的总有效率,观察组的治疗总有效率明显优于对照组,两组比较差异有统计学意义(P<0.05)。对照组早餐后、午餐后、晚餐后的血糖水平分别为(15.7±0.4)、(11.3±0.2)、(11.8±0.3)mmol/L,观察组的早餐后、午餐后、晚餐后的血糖水平分别为(10.2±0.3)、(9.5±0.4)、(8.2±0.2)mmol/L,观察组的餐后血糖水平明显优于对照组,两组比较差异有统计学意义(P<0.05);观察组的甲亢症状临床改善时间为(6.1±0.6)d明显优于对照组的(9.8±1.5)d,观察组的甲亢症状的临床改善时间也明显优于对照组,两组比较差异有统计学意义(P<0.05)。结论对甲状腺功能亢进合并糖尿病患者采用药物综合治疗法,有利于提升患者的治疗总有效率,同时还可以使患者的甲亢症状的临床改善时间及餐后血糖水平出现明显改善,值得临床推广。 展开更多
关键词 临床效果 甲状腺功能亢进合并糖尿 药物综合治疗法
下载PDF
Updates on treatment of irritable bowel syndrome 被引量:5
2
作者 Christopher W Hammerle Christina M Surawicz 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第17期2639-2649,共11页
Irritable bowel syndrome (IBS) is a highly prevalent gastrointestinal disorder characterized by abdominal pain and discomfort in association with altered bowel habits. It is estimated tD affect 10%-15% of the Wester... Irritable bowel syndrome (IBS) is a highly prevalent gastrointestinal disorder characterized by abdominal pain and discomfort in association with altered bowel habits. It is estimated tD affect 10%-15% of the Western population, and has a large impact on quality of life and (in)direct healthcare costs. IBS is a multifactorial disorder involving dysregulation within the brain-gut axis, and it is frequently associated with gastrointestinal motor and sensory dysfunction, enteric and central nervous system irregularities, neuroimmune dysregulation, and postinfectious inflammation. As with other functional medical disorders, the treatment for IBS can be challenging. Conventional therapy for those with moderate to severe symptoms is largely unsatisfactory, and the development of new and effective drugs is made difficult by the complex pathogenesis, variety of symptoms, and lack of objective clinical findings that are the hallmark of this disorder. Fortunately, research advances over the past several decades have provided insight into potential mechanisms responsible for the pathogenesis of IBS, and have led to the development of several promising pharmaceutical agents. In recent years there has been much publicity over several of these new IBS medications (alosetron and tegaserod) because of their reported association with ischemic colitis and cardiovascular disease. While these agents remain available for use under restricted prescribing programs, this highlights the need for continued development of safe and effective medication for IBS. This article provides a physiologicallybased overview of recently developed and frequently employed pharmaceutical agents used to treat IBS, and discusses some non-pharmaceutical options that may be beneficial in this disorder. 展开更多
关键词 Irritable bowel syndrome TREATMENT PHARMACOTHERAPY CHALLENGES OPPORTUNITIES
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部